News | April 22, 2024
Evotech and Variant Bio partner to develop fibrosis treatment
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The pilot plant is focused on scaling up beverage production and will support applications
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated
